Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- Check2 days agoChange DetectedPage now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' link has been removed.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location details, as well as the introduction of cabozantinib as a relevant drug. However, several key pieces of information related to Ewing sarcoma and other related topics have been removed.SummaryDifference2%
- Check23 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe page has been updated to reflect the latest version as v2.16.12, replacing the previous version v2.16.11. The phrasing regarding the last update has been clarified from 'Estimated' to a definitive statement.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has updated its versioning and date information, reflecting a new revision and the removal of outdated dates.SummaryDifference0.4%
Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.